Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30892502 | 0.83 | BRD4 (0.62) | BRD4HSD17B10ALDH1A1HPGDLMNA | |
| SCHEMBL10822262 | 0.83 | BRD4 (0.62) | BRD4HSD17B10ALDH1A1HPGDLMNA | |
| SCHEMBL4959476 | 0.81 | CA12 (0.57) | HSD17B10CA12CA1CA2CA7 | |
| SCHEMBL5187360 | 0.81 | CA12 (0.67) | HSD17B10CA12CA1CA2CA7 | |
| SCHEMBL30327328 | 0.77 | ADRA2C (0.64) | BRD4HSD17B10ALDH1A1LMNARAB9A | |
| SCHEMBL2342698 | 0.77 | ADRA2C (0.64) | BRD4HSD17B10ALDH1A1LMNARAB9A | |
| SCHEMBL10946928 | 0.74 | BRD4 (0.53) | BRD4HSD17B10ALDH1A1HPGDLMNA | |
| SCHEMBL28049662 | 0.74 | BRD4 (0.53) | BRD4HSD17B10NPSR1ALDH1A1HPGD | |
| SCHEMBL11771399 | 0.74 | PYGM (0.58) | BRD4ALDH1A1LMNAKDM4EAPOBEC3A | |
| SCHEMBL8886874 | 0.73 | HSD17B10 (0.66) | BRD4HSD17B10NPSR1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004405-A1 | COMPOUNDS HAVING ACTIVITY IN CORRECTING MUTANT CFTR CELLULAR PROCESSING | UNIVERSITAETSKLINIKUM MUENSTER (DE) | 2012-01-05 | — | — | US | disclosed |
| US-20120004405-A1 | COMPOUNDS HAVING ACTIVITY IN CORRECTING MUTANT CFTR CELLULAR PROCESSING | UNIVERSITAETSKLINIKUM MUENSTER (DE) | 2012-01-05 | — | — | US | disclosed |
| US-20120004405-A1 | COMPOUNDS HAVING ACTIVITY IN CORRECTING MUTANT CFTR CELLULAR PROCESSING | UNIVERSITAETSKLINIKUM MUENSTER (DE) | 2012-01-05 | — | — | US | disclosed |
| EP-2376429-A2 | COMPOUNDS HAVING ACTIVITY IN CORRECTING MUTANT CFTR CELLULAR PROCESSING | Universitätsklinikum Münster (DE) | 2011-10-19 | — | — | EP | disclosed |
| US-20110245335-A1 | NEW INHIBITORS FOR TREATING DISEASES ASSOCIATED WITH AN EXCESS TRANSPORT OF HYALURONAN | UNIVERSITAETSKLINIKUM MUENSTER (DE) | 2011-10-06 | — | — | US | disclosed |
| US-20110245335-A1 | NEW INHIBITORS FOR TREATING DISEASES ASSOCIATED WITH AN EXCESS TRANSPORT OF HYALURONAN | UNIVERSITAETSKLINIKUM MUENSTER (DE) | 2011-10-06 | — | — | US | disclosed |
| US-20110245192-A1 | NEW ACTIVATORS FOR TREATING AND/OR PREVENTING DISEASES OR MEDICAL CONDITIONS WHICH BENEFIT FROM AN INCREASED TRANSPORT OF HYALURONAN ACROSS A LIPID BILAYER | UNIVERSITAETSKLINIKUM MUENSTER (DE) | 2011-10-06 | — | — | US | disclosed |
| US-20110245192-A1 | NEW ACTIVATORS FOR TREATING AND/OR PREVENTING DISEASES OR MEDICAL CONDITIONS WHICH BENEFIT FROM AN INCREASED TRANSPORT OF HYALURONAN ACROSS A LIPID BILAYER | UNIVERSITAETSKLINIKUM MUENSTER (DE) | 2011-10-06 | — | — | US | disclosed |
| WO-2010066912-A2 | COMPOUNDS HAVING ACTIVITY IN CORRECTING MUTANT CFTR CELLULAR PROCESSING | Universitätsklinikum Münster (DE) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245192-A1 | NEW ACTIVATORS FOR TREATING AND/OR PREVENTING DISEASES OR MEDICAL CONDITIONS WHICH BENEFIT FROM AN INCREASED TRANSPORT OF HYALURONAN ACROSS A LIPID BILAYER | CD44, HABP2, ASAH2 | BRD4 2805/4885HSD17B10 265/4885CA12 1445/4885 |
| US-20110245335-A1 | NEW INHIBITORS FOR TREATING DISEASES ASSOCIATED WITH AN EXCESS TRANSPORT OF HYALURONAN | SLC10A1, ABCB11, HEXD | BRD4 2688/4885HSD17B10 165/4885CA12 1269/4885 |
| US-20120004405-A1 | COMPOUNDS HAVING ACTIVITY IN CORRECTING MUTANT CFTR CELLULAR PROCESSING | CFTR, ABCB11, SLC26A4 | BRD4 3953/4885HSD17B10 648/4885CA12 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.